Showing results (111-120 of 126) with videos related to

Sort By:
Pageof 13
Nature Medicine|December 8, 2018
Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myelomaGuy Ledergor, Assaf Weiner, Mor Zada, et al.
Haematologica|September 22, 2018
Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUXMeletios A Dimopoulos, Jesus San-Miguel, Andrew Belch, et al.
Nature Reviews. Clinical Oncology|July 7, 2025
EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myelomaMeletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.
The Lancet. Haematology|March 16, 2025
Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 studyAjai Chari, Cyrille Touzeau, Carolina Schinke, et al.
Leukemia|July 4, 2018
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysisBrian A Walker, Konstantinos Mavrommatis, Christopher P Wardell, et al.
Leukemia|August 12, 2020
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trialsLuciano J Costa, Benjamin A Derman, Susan Bal, et al.
The Lancet. Oncology|August 12, 2016
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaShaji Kumar, Bruno Paiva, Kenneth C Anderson, et al.
Science Advances|September 30, 2022
CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcomePaula Rodriguez-Marquez, Maria E Calleja-Cervantes, Guillermo Serrano, et al.
Blood|June 10, 2018
Identification of novel mutational drivers reveals oncogene dependencies in multiple myelomaBrian A Walker, Konstantinos Mavrommatis, Christopher P Wardell, et al.
The Journal of Pathology|February 22, 2018
Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemiaMaria J García-Barchino, Maria E Sarasquete, Carlos Panizo, et al.
Pageof 13